151 related articles for article (PubMed ID: 36221112)
1. CpG island status as an epigenetic alteration for NIS promoter in thyroid neoplasms; a cross-sectional study with a systematic review.
Zarkesh M; Arab N; Abooshahab R; Heydarzadeh S; Sheikholeslami S; Nozhat Z; Salehi Jahromi M; Fanaei SA; Hedayati M
Cancer Cell Int; 2022 Oct; 22(1):310. PubMed ID: 36221112
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of a New Distal Sodium/Iodide Symporter (NIS) enhancer (NDE) is associated with reduced NIS expression in thyroid tumors.
Galrão AL; Camargo RY; Friguglietti CU; Moraes L; Cerutti JM; Serrano-Nascimento C; Suzuki MF; Medeiros-Neto G; Rubio IG
J Clin Endocrinol Metab; 2014 Jun; 99(6):E944-52. PubMed ID: 24432988
[TBL] [Abstract][Full Text] [Related]
3. The Epigenetic Modification of
Sheikholeslami S; Azizi F; Ghasemi A; Alibakhshi A; Parsa H; Shivaee S; Zarif-Yeganeh M; Hedayati M; Teimoori-Toolabi L
Iran J Public Health; 2022 Mar; 51(3):634-642. PubMed ID: 35865047
[TBL] [Abstract][Full Text] [Related]
4. Methylation levels of sodium-iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression.
Galrão AL; Sodré AK; Camargo RY; Friguglietti CU; Kulcsar MA; Lima EU; Medeiros-Neto G; Rubio IG
Endocrine; 2013 Feb; 43(1):225-9. PubMed ID: 22945693
[TBL] [Abstract][Full Text] [Related]
5. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
6. Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer.
Sassa M; Hayashi Y; Watanabe R; Kikumori T; Imai T; Kurebayashi J; Kiuchi T; Murata Y
Thyroid; 2011 May; 21(5):511-7. PubMed ID: 21449767
[TBL] [Abstract][Full Text] [Related]
7.
Sheikholeslami S; Azizi F; Ghasemi A; Alibakhshi A; Parsa H; Tavangar SM; Shivaee S; Zarif Yeganeh M; Hedayati M; Teimoori-Toolabi L
Int J Endocrinol Metab; 2020 Oct; 18(4):e108510. PubMed ID: 33613681
[TBL] [Abstract][Full Text] [Related]
8. Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents.
Patel A; Jhiang S; Dogra S; Terrell R; Powers PA; Fenton C; Dinauer CA; Tuttle RM; Francis GL
Pediatr Res; 2002 Nov; 52(5):737-44. PubMed ID: 12409522
[TBL] [Abstract][Full Text] [Related]
9. Lack of correlation for sodium iodide symporter mRNA and protein expression and analysis of sodium iodide symporter promoter methylation in benign cold thyroid nodules.
Neumann S; Schuchardt K; Reske A; Reske A; Emmrich P; Paschke R
Thyroid; 2004 Feb; 14(2):99-111. PubMed ID: 15068624
[TBL] [Abstract][Full Text] [Related]
10. Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.
Mishra A; Pal L; Mishra SK
World J Surg; 2007 Sep; 31(9):1737-1742. PubMed ID: 17653791
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation in thyroid tumorigenesis.
Stephen JK; Chitale D; Narra V; Chen KM; Sawhney R; Worsham MJ
Cancers (Basel); 2011 Jun; 3(2):1732-43. PubMed ID: 21738852
[TBL] [Abstract][Full Text] [Related]
12. DNA Methylation-Based Method to Differentiate Malignant from Benign Thyroid Lesions.
Barros-Filho MC; Dos Reis MB; Beltrami CM; de Mello JBH; Marchi FA; Kuasne H; Drigo SA; de Andrade VP; Saieg MA; Pinto CAL; Kowalski LP; Rogatto SR
Thyroid; 2019 Sep; 29(9):1244-1254. PubMed ID: 31328658
[No Abstract] [Full Text] [Related]
13. Methylation markers differentiate thyroid cancer from benign nodules.
Stephen JK; Chen KM; Merritt J; Chitale D; Divine G; Worsham MJ
J Endocrinol Invest; 2018 Feb; 41(2):163-170. PubMed ID: 28612287
[TBL] [Abstract][Full Text] [Related]
14. Detection of global hypermethylation in well-differentiated thyroid neoplasms by immunohistochemical (5-methylcytidine) analysis.
Keelawat S; Thorner PS; Shuangshoti S; Bychkov A; Kitkumthorn N; Rattanatanyong P; Boonyayothin W; Poumsuk U; Ruangvejvorachai P; Mutirangura A
J Endocrinol Invest; 2015 Jul; 38(7):725-32. PubMed ID: 25740063
[TBL] [Abstract][Full Text] [Related]
15. B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1.
Choi YW; Kim HJ; Kim YH; Park SH; Chwae YJ; Lee J; Soh EY; Kim JH; Park TJ
Exp Mol Med; 2014 Nov; 46(11):e120. PubMed ID: 25378232
[TBL] [Abstract][Full Text] [Related]
16. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
17. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma.
Schagdarsurengin U; Gimm O; Dralle H; Hoang-Vu C; Dammann R
Thyroid; 2006 Jul; 16(7):633-42. PubMed ID: 16889486
[TBL] [Abstract][Full Text] [Related]
18. The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer.
Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Fanaei SA; Hedayati M; Azizi F
BMC Cancer; 2018 Dec; 18(1):1199. PubMed ID: 30509240
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of HHIP gene CpG island methylation in gastric cancer.
Song Y; Zuo Y
Oncol Lett; 2014 Nov; 8(5):2340-2344. PubMed ID: 25295121
[TBL] [Abstract][Full Text] [Related]
20. Spinal metastases due to thyroid carcinoma: an analysis of 202 patients.
Kushchayeva YS; Kushchayev SV; Carroll NM; Felger EA; Links TP; Teytelboym OM; Bonichon F; Preul MC; Sonntag VK; Van Nostrand D; Burman KD; Boyle LM
Thyroid; 2014 Oct; 24(10):1488-500. PubMed ID: 24921429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
